{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:33:58Z","timestamp":1794346438696,"version":"4.9.0"},"reference-count":55,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"PSC Support","award":["FARGO"],"award-info":[{"award-number":["FARGO"]}]},{"DOI":"10.13039\/100012357","name":"LifeArc","doi-asserted-by":"publisher","award":["P2022-0001"],"award-info":[{"award-number":["P2022-0001"]}],"id":[{"id":"10.13039\/100012357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,12,10]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD). The strong association between gut and liver inflammation has driven several pathogenic hypotheses to which the intestinal microbiome is proposed to contribute. Pilot studies of faecal microbiota transplantation (FMT) in PSC and IBD are demonstrated to be safe and associated with increased gut bacterial diversity. However, the longevity of such changes and the impact on markers of disease activity and disease progression have not been studied. The aim of this clinical trial is to determine the effects of repeated FMT as a treatment for PSC-IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO) is a phase IIa randomised placebo-controlled trial to assess the efficacy and safety of repeated colonic administration of FMT in patients with non-cirrhotic PSC-IBD. Fifty-eight patients will be recruited from six sites across England and randomised in a 1:1 ratio between active FMT or FMT placebo arms. FMT will be manufactured by the University of Birmingham Microbiome Treatment Centre, using stool collected from rigorously screened healthy donors. A total of 8\u2009weekly treatments will be delivered; the first through colonoscopic administration (week 1) and the remaining seven via once-weekly enema (up to week 8). Participants will then be followed on a 12-weekly basis until week 48 from the first treatment visit. The primary efficacy outcome will be to determine the effect of FMT on serum alkaline phosphatase values over time (end of study at 48 weeks). Key secondary outcomes will be to evaluate the impact of FMT on other liver biochemical parameters, PSC risk scores, circulating and imaging markers of liver fibrosis, health-related quality of life measures, IBD activity and the incidence of PSC-related clinical events. Key translational objectives will be to identify mucosal metagenomic, metatranscriptomic, metabolomic and immunological pathways associated with the administration of FMT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol was approved by the South Central\u2014Hampshire B Research Ethics Committee (REC 23\/SC\/0147). Participants will be required to provide written informed consent. The results of this trial will be disseminated through national and international presentations and peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      The trial was registered at ClinicalTrials.gov on 23 February 2024 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06286709\">NCT06286709<\/jats:ext-link>\n                      ). Weblink: Study Details | FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis | ClinicalTrials.gov.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-095392","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T20:41:58Z","timestamp":1736196118000},"page":"e095392","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06286709","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5382-3072","authenticated-orcid":false,"given":"Sarah","family":"Al-Shakhshir","sequence":"first","affiliation":[{"name":"National Institute of Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC) Center for Liver and Gastrointestinal Research, University of Birmingham, Birmingham, England, UK"},{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Nabil","family":"Quraishi","sequence":"additional","affiliation":[{"name":"University of Birmingham Institute of Cancer and Genomic Sciences, Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6300-3100","authenticated-orcid":false,"given":"Benjamin","family":"Mullish","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Imperial College London Faculty of Medicine, London, UK"},{"name":"Department of Hepatology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arzoo","family":"Patel","sequence":"additional","affiliation":[{"name":"National Institute of Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC) Center for Liver and Gastrointestinal Research, University of Birmingham, Birmingham, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Vince","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rowe","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Homer","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Jackson","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derick","family":"Gyimah","sequence":"additional","affiliation":[{"name":"Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahida","family":"Shabir","sequence":"additional","affiliation":[{"name":"University of Birmingham Microbiome Treatment Centre, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Manzoor","sequence":"additional","affiliation":[{"name":"University of Birmingham Microbiome Treatment Centre, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Cooney","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laith","family":"Alrubaiy","sequence":"additional","affiliation":[{"name":"Gastroenterology, St Mark's Hospital and Academic Institute, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Quince","sequence":"additional","affiliation":[{"name":"Food, Microbiome and Health Institute Strategic Programme, Quadram Institute Bioscience, Norwich, UK"},{"name":"Digital Biology, Earlham Institute, Norwich, Norfolk, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"van Schaik","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Infection, University of Birmingham, Birmingham, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hares","sequence":"additional","affiliation":[{"name":"Institute of Microbiology and Infection, University of Birmingham, Birmingham, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D","family":"Beggs","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"},{"name":"University of Birmingham Institute of Cancer and Genomic Sciences, Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Efstathiou","sequence":"additional","affiliation":[{"name":"University of Birmingham Institute of Cancer and Genomic Sciences, Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rimmer","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Weston","sequence":"additional","affiliation":[{"name":"National Institute of Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC) Center for Liver and Gastrointestinal Research, University of Birmingham, Birmingham, England, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Iqbal","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"},{"name":"University of Birmingham Institute of Cancer and Genomic Sciences, Birmingham, Birmingham, UK"},{"name":"University of Birmingham Microbiome Treatment Centre, University of Birmingham, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak J","family":"Trivedi","sequence":"additional","affiliation":[{"name":"National Institute of Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC) Center for Liver and Gastrointestinal Research, University of Birmingham, Birmingham, England, UK"},{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"2025121602493528000_15.1.e095392.1","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/S0140-6736(13)60096-3","article-title":"Primary sclerosing cholangitis","volume":"382","author":"Hirschfield","year":"2013","journal-title":"The Lancet"},{"key":"2025121602493528000_15.1.e095392.2","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"key":"2025121602493528000_15.1.e095392.3","doi-asserted-by":"crossref","first-page":"101002","DOI":"10.1016\/j.lanepe.2024.101002","article-title":"Past, current, and future trends in the prevalence of primary sclerosing cholangitis and inflammatory bowel disease across England (2015-2027): a nationwide, population-based study","volume":"44","author":"Crothers","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2025121602493528000_15.1.e095392.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.08.039"},{"key":"2025121602493528000_15.1.e095392.5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322362"},{"key":"2025121602493528000_15.1.e095392.6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26565"},{"key":"2025121602493528000_15.1.e095392.7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.02.038"},{"key":"2025121602493528000_15.1.e095392.8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.28128","article-title":"Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists","volume":"63","author":"Trivedi","year":"2016","journal-title":"Hepatology"},{"key":"2025121602493528000_15.1.e095392.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2011.10.007"},{"key":"2025121602493528000_15.1.e095392.10","first-page":"124","article-title":"Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence","volume":"32","author":"Mertz","year":"2019","journal-title":"Ann Gastroenterol"},{"key":"2025121602493528000_15.1.e095392.11","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.4.522"},{"key":"2025121602493528000_15.1.e095392.12","doi-asserted-by":"publisher","DOI":"10.1067\/mge.2002.125367"},{"key":"2025121602493528000_15.1.e095392.13","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MEG.0000000000000576","article-title":"Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies","volume":"28","author":"Zheng","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025121602493528000_15.1.e095392.14","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJY113"},{"key":"2025121602493528000_15.1.e095392.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2013.06.013"},{"key":"2025121602493528000_15.1.e095392.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.12.002"},{"key":"2025121602493528000_15.1.e095392.17","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312354"},{"key":"2025121602493528000_15.1.e095392.18","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/ecco-jcc\/jjaa021","article-title":"A Pilot Integrative Analysis of Colonic Gene Expression, Gut Microbiota, and Immune Infiltration in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Association of Disease With Bile Acid Pathways","volume":"14","author":"Quraishi","year":"2020","journal-title":"J Crohns Colitis"},{"key":"2025121602493528000_15.1.e095392.19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.058"},{"key":"2025121602493528000_15.1.e095392.20","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jhep.2023.05.038","article-title":"Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation","volume":"79","author":"Braadland","year":"2023","journal-title":"J Hepatol"},{"key":"2025121602493528000_15.1.e095392.21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/MOG.0000000000000809","article-title":"Mucosal immunity in primary sclerosing cholangitis: from the bowel to bile ducts and back again","volume":"38","author":"Liaskou","year":"2022","journal-title":"Curr Opin Gastroenterol"},{"key":"2025121602493528000_15.1.e095392.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-018-0333-1"},{"key":"2025121602493528000_15.1.e095392.23","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1038\/s42255-021-00452-1","article-title":"Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling","volume":"3","author":"Schneider","year":"2021","journal-title":"Nat Metab"},{"key":"2025121602493528000_15.1.e095392.24","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326500"},{"key":"2025121602493528000_15.1.e095392.25","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S0168-8278(23)00616-5","article-title":"Oral vancomycin induces remission in PSC-IBD, which is associated with a reduction in bile salt hydrolase and colonic amine oxidase activity","volume":"78","author":"Quraishi","year":"2023","journal-title":"J Hepatol"},{"key":"2025121602493528000_15.1.e095392.26","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12232"},{"key":"2025121602493528000_15.1.e095392.27","doi-asserted-by":"crossref","first-page":"457","DOI":"10.15403\/jgld.2014.1121.254.rah","article-title":"A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study","volume":"25","author":"Rahimpour","year":"2016","journal-title":"J Gastrointestin Liver Dis"},{"key":"2025121602493528000_15.1.e095392.28","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31816fee95"},{"key":"2025121602493528000_15.1.e095392.29","doi-asserted-by":"crossref","unstructured":"Quraishi MN , Cheesbrough J , Rimmer P , et al . Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures. J Crohns Colitis 2024.:jjae189. doi:10.1093\/ecco-jcc\/jjae189","DOI":"10.1093\/ecco-jcc\/jjae189"},{"key":"2025121602493528000_15.1.e095392.30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jhin.2018.06.024","article-title":"Point-prevalence survey of carbapenemase-producing Enterobacteriaceae and vancomycin-resistant enterococci in adult inpatients in a university teaching hospital in the UK","volume":"100","author":"Wilson","year":"2018","journal-title":"J Hosp Infect"},{"key":"2025121602493528000_15.1.e095392.31","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/MEG.0b013e3282f5197e","article-title":"Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study","volume":"20","author":"Vleggaar","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2025121602493528000_15.1.e095392.32","unstructured":"Allegretti JA , Kassam Z , Carrellas M . Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial. 2019. Available: http:\/\/spiral.imperial.ac.uk\/handle\/10044\/1\/66365"},{"key":"2025121602493528000_15.1.e095392.33","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jhin.2024.03.001","article-title":"The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines","volume":"148","author":"Mullish","year":"2024","journal-title":"J Hosp Infect"},{"key":"2025121602493528000_15.1.e095392.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05220.x"},{"key":"2025121602493528000_15.1.e095392.35","doi-asserted-by":"crossref","unstructured":"Quraishi MN , Yalchin M , Blackwell C , et al . O9\u2005STOP-colitis pilot: prospective, open-label, randomised study comparing nasogastric versus colonic fmt delivery in ulcerative colitis. Abstracts of the BSG Campus, 21\u201329 January 2021; 2021 doi:10.1136\/gutjnl-2020-bsgcampus.9","DOI":"10.1136\/gutjnl-2020-bsgcampus.9"},{"key":"2025121602493528000_15.1.e095392.36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29306"},{"key":"2025121602493528000_15.1.e095392.37","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","article-title":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial","volume":"29","author":"Routy","year":"2023","journal-title":"N Med"},{"key":"2025121602493528000_15.1.e095392.38","doi-asserted-by":"crossref","first-page":"949490","DOI":"10.3389\/fimmu.2022.949490","article-title":"Antitumor effects of fecal microbiota transplantation: Implications for microbiome modulation in cancer treatment","volume":"13","author":"Xu","year":"2022","journal-title":"Front Immunol"},{"key":"2025121602493528000_15.1.e095392.39","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030659","article-title":"STOP-Colitis pilot trial protocol: a prospective, open-label, randomised pilot study to assess two possible routes of faecal microbiota transplant delivery in patients with ulcerative colitis","volume":"9","author":"Quraishi","year":"2019","journal-title":"BMJ Open"},{"key":"2025121602493528000_15.1.e095392.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-45173-4"},{"key":"2025121602493528000_15.1.e095392.41","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/S2666-5247(21)00036-7","article-title":"The journey towards safely restarting faecal microbiota transplantation services in the UK during the COVID-19 era","volume":"2","author":"Quraishi","year":"2021","journal-title":"Lancet Microbe"},{"key":"2025121602493528000_15.1.e095392.42","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02327-16"},{"key":"2025121602493528000_15.1.e095392.43","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00161-21","article-title":"Fecal Microbiota Transplantation Donor Screening Updates and Research Gaps for Solid Organ Transplant Recipients","volume":"60","author":"Mehta","year":"2022","journal-title":"J Clin Microbiol"},{"key":"2025121602493528000_15.1.e095392.44","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313017"},{"key":"2025121602493528000_15.1.e095392.45","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/hep.30479","article-title":"Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System","volume":"69","author":"Goode","year":"2019","journal-title":"Hepatology"},{"key":"2025121602493528000_15.1.e095392.46","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313681"},{"key":"2025121602493528000_15.1.e095392.47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/hep.29664","article-title":"Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"2025121602493528000_15.1.e095392.48","doi-asserted-by":"publisher","DOI":"10.1007\/BF00647843"},{"key":"2025121602493528000_15.1.e095392.49","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol"},{"key":"2025121602493528000_15.1.e095392.50","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(89)90905-0"},{"key":"2025121602493528000_15.1.e095392.51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000518131","article-title":"Assessment of Endoscopic Disease Activity in Ulcerative Colitis: Is Simplicity the Ultimate Sophistication?","volume":"7","author":"Sharara","year":"2022","journal-title":"Inflamm Intest Dis"},{"key":"2025121602493528000_15.1.e095392.52","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(04)01878-4"},{"key":"2025121602493528000_15.1.e095392.53","unstructured":"Common terminology criteria for adverse events (CTCAE). 2017."},{"key":"2025121602493528000_15.1.e095392.54","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.4103\/sja.SJA_559_18","article-title":"The CONSORT statement","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"2025121602493528000_15.1.e095392.55","unstructured":"ICMJE recommendations . Defining the role of authors and contributors. 2024. Available: https:\/\/www.icmje.org\/recommendations\/browse\/roles-and-responsibilities\/defining-the-role-of-authors-and-contributors.html"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-095392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:49:48Z","timestamp":1765882188000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-095392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/bmjopen-2024-095392"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095392","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095392.supp1","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095392.supp2","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095392.supp3","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095392.supp4","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095392.supp5","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095392.supp6","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095392.supp7","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095392.supp8","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1136\/bmjopen-2024-095392.supp9","asserted-by":"subject"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}